Now trading at a price of $38.35, Legend Biotech has moved 3.1% so far today.
Legend Biotech returned losses of -42.5% last year, with its stock price reaching a high of $65.45 and a low of $30.17. Over the same period, the stock underperformed the S&P 500 index by -52.0%. AThe company's 50-day average price was $35.71. Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Based in Somerset, NJ, the Mid-Cap Health Care company has 2,600 full time employees. Legend Biotech has not offered a dividend during the last year.
An Excellent Current Ratio but Negative Cash Flows:
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue (k) | $59,980 | $75,000 | $68,826 | $117,005 | $285,143 | $280,514 |
| Net Margins | -169% | -355% | -586% | -381% | -182% | -28% |
| Net Income (k) | -$101,590 | -$266,373 | -$403,582 | -$446,349 | -$518,254 | -$77,989 |
| Earnings Per Share | -$0.51 | -$1.13 | -$1.43 | -$1.4 | -$1.47 | -$0.21 |
| EPS Growth | n/a | -121.57% | -26.55% | 2.1% | -5.0% | 85.71% |
| Free Cash Flow (k) | -$83,065 | -$223,005 | -$198,465 | -$201,281 | -$393,276 | $13,867 |
| Total Debt (k) | $9,586 | $5,238 | $120,462 | $260,932 | $281,328 | $291,559 |
| Current Ratio | 1.62 | 5.14 | 4.14 | 3.69 | 6.92 | 4.84 |
Legend Biotech does not have a meaningful trailing P/E ratio since its earnings per share are negative. Its forward EPS guidance is negative too, at $-0.67. The average P/E ratio for the Health Care sector is 26.07. Furthermore, Legend Biotech is likely overvalued compared to the book value of its equity, since its P/B ratio of 6.77 is higher than the sector average of 3.53. Overall, Legend Biotech's lofty valuation in terms of earnings and assets is to some extent attenuated by its strong cash flow trend and reasonable levels of debt.
Legend Biotech Has an Average Rating of Buy:
The 21 analysts following Legend Biotech have set target prices ranging from $53.12 to $95.0 per share, for an average of $77.92 with a buy rating. The company is trading -50.8% away from its average target price, indicating that there is an analyst consensus of strong upside potential.
Legend Biotech has an above average percentage of its shares sold short because 13.6% of the company's shares are sold short. Institutions own 55.5% of the company's shares, and the insider ownership rate stands at 1.33%, suggesting a small amount of insider investors. The largest shareholder is FMR, LLC, whose 7% stake in the company is worth $515,760,139.
